BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20171029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171125
DTEND;VALUE=DATE:20171227
DTSTAMP:20260729T184310
CREATED:20171125T213731Z
LAST-MODIFIED:20171125T213731Z
UID:19418-1511568000-1514332799@ces.b2sg.org
SUMMARY:Postdoctoral Fellow: ­­­­­­­­­­Cancer Immunotherapy
DESCRIPTION:Cancer immunotherapy represents a paradigm shift in the management of cancer. Recent successes with antibody directed therapies for immune modulators such as CTLA4 and PD1/PDL-1 axis have altered the landscape of systemic therapy for solid and hematologic malignancies. Among various strategies to improve cancer immunotherapy\, epigenetic targets have emerged as prominent actionable targets to enhance anti-tumor immune responses and suppressing tolerogenic tumor microenvironment. Our laboratory is focused on mechanisms by which various epigenetic molecules impact the immune system to identify novel approaches to cancer immunotherapy. \n  \nAlternative approaches to enhancing cancer immunotherapy are to modulate immunologic consequences to existing cytotoxic therapy\, such as radiation therapy. More recently\, the concept of immunogenic cell death induced by XRT has been proposed. Immunogenic cell death is associated with release of HMG-B1 and ATP as DAMPs (damage-associated molecular pattern)\, which provides the “Danger Signal” required for effective adaptive immune responses. Surface translocation of calreticulin promotes antigen presentation by facilitating phagocytic uptake by dendritic cells (DC). We are therefore currently investigating how to promote tumor specific immune responses by radiation therapy. \n  \nPosition Highlights: \n\nInvolved mentorship by Dr. Kim\n\n\nGain knowledge base in cancer immunotherapy\, immune activation and tolerance mechanisms\, molecular immunology\nDevelop expertise in epigenetic regulation of the immune system\nTrain in in vivo and in vitro methodologies in immunologic research\n\n  \nThe Ideal Candidate: \n\nScientifically inquisitive and enthusiastic to learn new approaches\nCollaborate well with other researchers\nBackgrounds in immunologic research\nFamiliar with flow cytometry and molecular work\n\n  \nResponsibilities: \n\nRead and discuss relevant literature\nDesign and conduct experiments\nPresent at the lab meetings and scientific conferences\nResearch methodologies will mostly include flow cytometry\, confocal microscopy\, proximity ligation assay\, Western blot and other molecular work\, ex vivo and in vivo mouse studies.\n\n  \nCredentials and Qualifications: \n\nPh.D. or M.D. in Immunology\, Molecular Biology\, Cell Biology\, or Cancer Biology.\n\n  \nA competitive salary and benefits package will be offered to the successful candidate. Interested applicants should send a single PDF file that includes a current CV with recent publications\, a personal statement of scientific interests and goals (2-page maximum) and contact information for three references to Dr. Sungjune Kim at Sungjune.kim@moffitt.org.
URL:https://ces.b2sg.org/event/moffitt-nov2517/
LOCATION:Moffitt Cancer Center Magnolia Campus\, 12902 USF Magnolia Drive\, Tampa\, FL\, 33612\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/Moffitt-1.jpg
END:VEVENT
END:VCALENDAR